Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | Novel drugs for myeloma thromboprophylaxis

Heinz Ludwig • 13 May 2020
COMy Virtual 2020
Multiple Myeloma Apixaban Edoxaban

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on myeloma thromboprophylaxis, specifically, the use of novel anticoagulants such as edoxaban and apixaban. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Heinz Ludwig

2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
2:02
Issues with CAR-T slot allocation in myeloma & the promise of locally manufactured products
Heinz Ludwig • 27 Sep 2023
3:49
Advances in technologies used to assess immune function in myeloma
Heinz Ludwig • 27 Sep 2023
2:59
Managing COVID-19 risks and exposures in patients with myeloma
Heinz Ludwig • 12 May 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals